Over 90% Accuracy Identifying the Four Main Subtypes of Lung Cancer Using Small Tumor Quantities

PHILADELPHIA, PA and REHOVOT, ISRAEL–(Marketwire – Jul 14, 2011) – Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces that it has launched miRview® lung, the Company’s advanced microRNA test that differentiates neuroendocrine tumors from non-small cell lung tumors (NSCLC), and then further subtypes neuroendocrine tumors into small cell lung cancer and carcinoid; and subtypes NSCLC tumors into squamous and non-squamous. miRview® lung will be marketed in the U.S. by Rosetta Genomics’ oncology sales team and will be available internationally through the Company’s various distribution partners.